09/01/2026
The field of RAS-targeted drug development continues to advance, bringing new opportunities and challenges across oncology research. Nowack and Tsatsos will be attending the RAS-Targeted Drug Development Summit in Boston, where experts will explore emerging therapeutic strategies, resistance mechanisms, patient selection, and more. If you’ll be there, connect with Björn or Niko to discuss how reliable reference materials can support oncology assay development and validation.